Related Experiment Video
Updated: Sep 12, 2025

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic
Samuel J Dicken1,2,3, Friedrich C Jassil4,5,6,7, Adrian Brown4,5,6
1Centre for Obesity Research, Division of Medicine, University College London (UCL), London, UK. samuel.dicken.20@ucl.ac.uk.
Abstract:
Ultraprocessed food (UPF) consumption is associated with noncommunicable disease risk, yet no trial has assessed its health impact within the context of national dietary guidelines. In a 2 × 2 crossover randomized controlled feeding trial, 55 adults in England (body mass index ≥25 to <40 kg m-2, habitual UPF intake ≥50% kcal day-1) were provided with two 8-week ad libitum diets following the UK Eatwell Guide: (1) minimally processed food (MPF) and (2) UPF, in a random order. Twenty-eight people were randomized to MPF then UPF, and 27 to UPF then MPF; 50 participants comprised the intention-to-treat sample. The primary outcome was the within-participant difference in percent weight change (%WC) between diets, from baseline to week 8. Participants were blinded to the primary outcome. MPF (%WC, -2.06 (95% confidence interval (CI), -2.99, -1.13) and UPF (%WC, -1.05 (95% CI, -1.98, -0.13)) resulted in weight loss, with significantly greater %WC on MPF (Δ%WC, -1.01 (95% CI, -1.87, -0.14), P = 0.024; Cohen's d, -0.48 (95% CI, -0.91, -0.06)). Mild gastrointestinal adverse events were common on both diets. Findings indicate greater weight loss on MPF than UPF diets and needing dietary guidance on food processing in addition to existing recommendations. Clinicaltrials.gov registration: NCT05627570 .
Related Concept Videos
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Atherosclerosis III: Management

